Imatinib: A Breakthrough of Targeted Therapy in Cancer

摘要: Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in form selective inhibitors (TKIs) has transformed approach management various cancers and represents a therapeutic breakthrough. Imatinib was one first cancer therapies show potential for such targeted action. Imatinib, an oral therapy, inhibits kinases specifically BCR-ABL, c-KIT, PDGFRA. Apart from its remarkable success CML GIST, benefits other tumors caused by Imatinib-specific abnormalities PDGFR c-KIT. also been proven be effective steroid-refractory chronic graft-versus-host disease because anti-PDGFR This paper comprehensive review role oncology.